Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of gemcitabine plus either docetaxel or irinotecan in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Key facts

Study ID

NCT00004139

Run by

Alliance for Clinical Trials in Oncology

People needed

80

Starts

1999-09-01

Expected to finish

2006-01-01

Last updated by the study team

2016-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Vincent T. Lombardi Cancer Research Center, Georgetown University — Washington D.C., District of Columbia, United States
• Walter Reed Army Medical Center — Washington D.C., District of Columbia, United States
• Barnes-Jewish Hospital — St Louis, Missouri, United States
• CCOP - Southern Nevada Cancer Research Foundation — Las Vegas, Nevada, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• CCOP - Greenville — Greenville, South Carolina, United States
• University of Tennessee, Memphis Cancer Center — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.